Expanding its therapeutic footprint beyond cardiology, CNS, respiratory, and metabolic care, Sanovel has integrated controlled-release urology solutions into its manufacturing portfolio. Developed at the company’s R&D Center and integrated manufacturing campus, the propiverine formulation combines antimuscarinic action with calcium-channel antagonism to deliver antispasmodic efficacy across bladder smooth muscle tissue.
Overactive bladder affects approximately 20% of the global adult population, with higher prevalence observed in females (21.9%) compared to males (16.1%). Characterized by sudden urinary urgency, frequency, and urge incontinence, the condition frequently drives sleep fragmentation, professional impairment, and social withdrawal. The sustained-release formulation provides once-daily dosing convenience to improve long-term therapy compliance.
Dual Dosing Architecture and Neurogenic Coverage
The product has been launched in two distinct strengths tailored to clinical indications:
30 mg SR: Indicated for standard overactive bladder symptoms, including urinary frequency and urgency incontinence.
45 mg SR: Specifically indicated for controlling symptoms in patients presenting with neurogenic detrusor overactivity (detrusor hyperreflexia) secondary to spinal cord injuries.
Executive Perspective from Filiz Evsenel
Filiz Evsenel, Strategic Business Unit Manager at Sanovel, remarked:
For more than 40 years, Sanovel has committed itself to advancing public health by introducing innovative and value-added therapies to medicine. We maintain comprehensive pipelines spanning pain, cardiology, CNS, respiratory, and endocrinology. Today, entering urology with our proprietary propiverine formulation represents an important milestone reflecting our technology-oriented pharmaceutical vision.
Engineered and manufactured domestically at our advanced R&D Center and Production Campus, this formulation provides a dependable clinical alternative. We remain dedicated to broadening our urology portfolio with high-barrier products that enhance patients' psychosocial wellbeing and deliver proven options to healthcare professionals.
About Sanovel
Founded in 1983 by Pharmacist Erol Toksöz, Sanovel is an established leader in the Turkish pharmaceutical sector, featuring a portfolio of over 60 brands, 180+ commercial products, and an annual manufacturing output of 200 million packs. Audited and certified with European cGMP standards and US FDA approval, the company leverages high-barrier R&D to export across 50+ countries on five continents. Supported by 1,750 employees, Sanovel continues to develop first-to-market generic formulations and specialized pharmaceutical treatments.
